<- Go Home

Parexel International Corporation

Parexel International Corporation operates as a biopharmaceutical outsourcing company that provides clinical research and logistics, medical communications, consulting, and technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company offers clinical development, including translational medicine, early phase, phase II-III, phase IIIb/IV, biostatistics, clinical data management, clinical supply chain management, decentralized clinical trials, medical monitoring and consulting, medical writing, patient sensors, pharmacovigilance, and risk-based quality management (RBQM); outsourcing services, including functional services provider (FSP), strategic partnerships, and meeting management and logistics; consulting, including regulatory affairs consulting, clinical development strategy and planning, GxP compliance consulting, regulatory outsourcing, clinical trial regulatory services, market access and HEOR consulting, and commercial strategy (health advances); medical affairs, including the medical affairs company (TMAC), medical communications, and expanded access services; real-world evidence and late phase, including epidemiology, observational studies, and real-world data sciences; industry solutions, including pharma solutions and medical devices; and development phase solutions. Parexel International Corporation has strategic agreements with Microsoft Corporation, Synairgen plc, and CTC North GmbH & Co. KG. The company was incorporated in 1983 and is based in Newton, Massachusetts, with branches in Waltham and Billerica, Massachusetts, and Uxbridge, United Kingdom. It has additional locations throughout the world.

Market Cap

EUR 4.5B

Volume

885.8K

Cash and Equivalents

EUR 302.7M

EBITDA

EUR 340.1M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

EUR 740.1M

Profit Margin

34.95%

52 Week High

EUR 88.10

52 Week Low

EUR 51.16

Dividend

N/A

Price / Book Value

7.09

Price / Earnings

42.76

Price / Tangible Book Value

-108.19

Enterprise Value

N/A

Enterprise Value / EBITDA

N/A

Operating Income

EUR 233.7M

Return on Equity

16.93%

Return on Assets

6.72

Cash and Short Term Investments

EUR 302.7M

Debt

EUR 671.5M

Equity

EUR 634.5M

Revenue

EUR 2.1B

Unlevered FCF

EUR 255.3M

Sector

Life Sciences Tools and Services

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches